Vancouver, B.C. – November 4, 2021 – Origin Therapeutics Holdings Inc. (CSE: ORIG Proposed) (the “Company” or “Origin Therapeutics”) an actively managed investment issuer focused on making equity investments in psychedelics-related companies, is announcing that its portfolio company Tripsitter Clinic Corp. (“Tripsitter”) has expanded its service to patients in Arizona, Colorado, Michigan, Washington, Florida, New York, Ohio, and Virginia. These additional states build on the success that Tripsitter has already achieved in California and Illinois.
Tripsitter offers at-home ketamine therapy directed virtually by a physician. It broadens access to transformational psychedelic therapy by making it possible to access from the comfort of the patient’s home, on their schedule.
Ketamine is an anesthetic medication that was approved for medical use by the U.S. Food and Drug Administration (FDA) in 1970.
“Our sessions use ketamine at low, therapeutic doses,” said John Huber, CEO of Tripsitter. “Ketamine allows individuals to view their own patterned behavior with renewed clarity and enables them to change patterns of behavior and thought. We are very proud of our continued expansion across the U.S. and are receiving very positive feedback from patients.”
Origin Therapeutics is focused on identifying and investing in private, early-stage companies in the psychedelics industry. The Company manages investments via advisory support roles to help boost portfolio company growth.
“Expansion to these additional states is an exciting milestone for Tripsitter,” said Origin Therapeutics CEO, Alexander Somjen. “There is growing interest in this sector, Tripsitter sits at the intersection of two rapidly growing trends: telehealth and psychedelic therapy. We anticipate this launch is just the beginning of what should be steady progress from Tripsitter as it smartly builds a network of providers across the United States market.”
About TripSitter Clinic Corp
Tripsitter Clinic Corp. is a mobile-first, responsive web app that acts as a virtual clinic, connecting patients with an experienced medical practitioner. TripSitter operates as a “software as a service” (SaaS) platform, functioning as the intermediary between patient and practitioner attempting to replicate the successful results of the “Yale Protocol” through a Telehealth delivery platform using different mechanisms such as nasal sprays and troches. Learn more at www.tripsitter.clinic